Skip to Content

Glioma Genome-Wide Association Study (GWAS)

From the Cancer Genetic Markers of Susceptibility (CGEMS) Project

We conducted a new independent GWAS of glioma using 1,856 cases and 4,955 controls from 14 cohort studies belonging to the Cohort Consortium, 3 case-control studies, and 1 population-based case only study.  Cases were newly diagnosed glioma [ICDO-3 codes 9380-9480 or equivalent], and controls were cancer-free at the time of glioma diagnosis.  Cases and 2,429 newly genotyped controls (pre-QC) were scanned with the Illumina 660W chip.   Newly genotyped controls for this project were selected in a 2:1 ratio, frequency matched on age, sex and race/ethnicity.  GWAS data were already available on 2,591 controls and 12 cases from cohorts that had participated in the PANSCAN, CGEMS studies and the NCI lung cancer GWAS studies.  Each participating study obtained informed consent from study participants and approval from its Institutional Review Board (IRB) for this study and obtained IRB certification permitting data sharing in accordance with the NIH Policy for Sharing of Data Obtained in NIH Supported or Conducted Genome-Wide Association Studies (GWAS).

Obtain additional information or apply for access to the Glioma Genome-Wide Association Study.